Literature DB >> 6333253

Circulating proalbumin associated with a variant proteinase inhibitor.

S O Brennan, M C Owen, D R Boswell, J H Lewis, R W Carrell.   

Abstract

The unique finding of normal proalbumin in human plasma provides an insight into the mechanism of propeptide cleavage. Proalbumin, present as 1-5% of the total albumin, was found in a boy whose prime problem was the presence of a mutant proteinase inhibitor, alpha 1-antitrypsin Pittsburgh (358 Met----Arg) [2]. The inferred structure of human proalbumin was confirmed as Arg-Gly-Val-Phe-Arg-Arg-Alb. On incubation with various enzymes (trypsin, tryptase, thrombin, chymotrypsin, chymase and cathepsin B), only trypsin was capable of converting proalbumin to albumin. There was no conversion when proalbumin was incubated with whole blood, plasma or serum. However, intravenous injection of proalbumin into a rat resulted in complete conversion to albumin, the half-life of this process being 6 h. We conclude that propeptide cleavage is dependent on a serine proteinase which is inhibited intracellularly, by the mutant inhibitor, and that all the albumin in the boy was secreted as proalbumin, but was subjected to a separate cleavage process after export from the hepatocyte.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6333253     DOI: 10.1016/0304-4165(84)90029-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Albumin Redhill (-1 Arg, 320 Ala----Thr): a glycoprotein variant of human serum albumin whose precursor has an aberrant signal peptidase cleavage site.

Authors:  S O Brennan; T Myles; R J Peach; D Donaldson; P M George
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

Review 2.  Endo/exo-proteolysis in neoplastic progression and metastasis.

Authors:  Abdel-Majid Khatib; Daniel Bassi; Geraldine Siegfried; Andres J P Klein-Szanto; L'Houcine Ouafik
Journal:  J Mol Med (Berl)       Date:  2005-08-26       Impact factor: 4.599

3.  Met 358 to Arg mutation of alpha 1-antitrypsin associated with protein C deficiency in a patient with mild bleeding tendency.

Authors:  D Vidaud; J Emmerich; M Alhenc-Gelas; J Yvart; J N Fiessinger; M Aiach
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

4.  Endoproteolytic processing of recombinant proalbumin variants by the yeast Kex2 protease.

Authors:  E C Ledgerwood; P M George; R J Peach; S O Brennan
Journal:  Biochem J       Date:  1995-05-15       Impact factor: 3.857

5.  Activation-coupled membrane-type 1 matrix metalloproteinase membrane trafficking.

Authors:  Yi I Wu; Hidayatullah G Munshi; Scott J Snipas; Guy S Salvesen; Rafael Fridman; M Sharon Stack
Journal:  Biochem J       Date:  2007-10-15       Impact factor: 3.857

Review 6.  Potential opportunity in the development of new therapeutic agents based on endogenous and exogenous inhibitors of the proprotein convertases.

Authors:  Yannick Bontemps; Nathalie Scamuffa; Fabien Calvo; Abdel-Majid Khatib
Journal:  Med Res Rev       Date:  2007-09       Impact factor: 12.944

Review 7.  The Path to Therapeutic Furin Inhibitors: From Yeast Pheromones to SARS-CoV-2.

Authors:  Gary Thomas; Frédéric Couture; Anna Kwiatkowska
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.